Filgotinib as rheumatoid arthritis therapy.
Autoimmune disorders
Filgotinib
Janus kinase 1 (JAK1) inhibitors
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
Tyrosine kinase inhibitors
Journal
Drugs of today (Barcelona, Spain : 1998)
ISSN: 1699-3993
Titre abrégé: Drugs Today (Barc)
Pays: Spain
ID NLM: 101160518
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
entrez:
29
9
2021
pubmed:
30
9
2021
medline:
2
10
2021
Statut:
ppublish
Résumé
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and progressive disability when inflammation cannot be sufficiently controlled. Despite treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biological DMARDs (bDMARDs), up to 30% of RA patients do not reach or fail to maintain a good response over time. The recent introduction of Janus kinase inhibitors (JAKis) has widened the rheumatologist's armamentarium. Filgotinib, a selective JAK1 inhibitor, has been approved by the European Medicines Agency (EMA) for treatment of RA. Phase II and III studies highlighted filgotinib safety and efficacy in RA patients naive to DMARDs or with inadequate response to csDMARDs and bDMARDs. Filgotinib is administered orally at 200 mg every day. For patients older than 75 years or with moderate to severe renal impairment, a dose of filgotinib 100 mg every day is recommended.
Identifiants
pubmed: 34586102
pii: 3317241
doi: 10.1358/dot.2021.57.9.3317241
doi:
Substances chimiques
Antirheumatic Agents
0
GLPG0634
0
Pyridines
0
Triazoles
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
543-550Informations de copyright
Copyright 2021 Clarivate Analytics.